Several possible limitations should be noted. © 2009 by the American Diabetes Association. Corresponding author: Robert S. Rosenson. CONCLUSIONS In patients with the metabolic syndrome, statin-induced changes in LDL cholesterol do not accurately reflect changes in LDL particle concentration. RSV increased HDL cholesterol, and both statins increased HDL particle concentration compared with placebo. Effects of Rosuvastatin and Atorvastatin on LDL and HDL Particle Concentrations in Patients With Metabolic Syndrome, Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), American College of Cardiology Foundation, Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation, Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel, Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women, Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial, LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study—implications for LDL management, The metabolic syndrome: targeting dyslipidemia to reduce coronary risk, Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study, A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study, Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy, Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial, Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practice, Physiological role and clinical relevance of high-density lipoprotein subclasses, Indices of reverse cholesterol transport in subjects with metabolic syndrome after treatment with rosuvastatin, Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non–high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapy II) trial, Incremental Risk of Developing Severe COVID-19 Among Mexican Patients With Diabetes Attributed to Social and Health Care Access Disadvantages, A Randomized Controlled Trial to Evaluate the Effects of a Smartphone Application-Based Lifestyle Coaching Program on Gestational Weight Gain, Glycemic Control, Maternal, and Neonatal Outcomes in Women With Gestational Diabetes Mellitus: The SMART-GDM Study, Glucose-Dependent Insulinotropic Peptide in the High-Normal Range Is Associated With Increased Carotid Intima-Media Thickness, Antidiabetes Agents and Incident Depression: A Nationwide Population-Based Study, Sex Differences in Rates of Change and Burden of Metabolic Risk Factors Among Adults Who Did and Did Not Go On to Develop Diabetes: Two Decades of Follow-up From the Tehran Lipid and Glucose Study, Relative Risk of Cardiovascular Disease Is Higher in Women With Type 2 Diabetes, but Not in Those With Prediabetes, as Compared With Men, Institutional Subscriptions and Site Licenses, Special Podcast Series: Therapeutic Inertia, Special Podcast Series: Influenza Podcasts, http://creativecommons.org/licenses/by-nc-nd/3.0/. β-Quantification was performed to provide the most accurate measure of LDL cholesterol in the presence of high triglyceride levels. Lipitor (atorvastatin) is an HMG-CoA reductase inhibitor (a “statin” drug) used to lower blood cholesterol levels. has served on the speakers' bureau of AstraZeneca, owns stock in LipoScience, and has received consulting fees and honoraria from LipoScience. In nearly all prospective studies, LDL particle concentration or apoB has been a stronger predictor of cardiovascular outcomes than LDL cholesterol. We sought to determine the efficacy of statin therapy in achieving LDL cholesterol targets set by the National Cholesterol Education Program Adult Treatment Panel III (ATP III) and the corresponding numbers of patients who achieved LDL particle concentration targets below the 50th percentile (<1,300 nmol/l) and below the 20th percentile (<1,000 nmol/l) based on values established by the Multi-Ethnic Study of Atherosclerosis (MESA) (10). Neither statin showed a statistically significant effect on apoA-I compared with placebo; however, increases in apoA-I were significantly greater with RSV than with ATV at 6 (P = 0.001) and 12 weeks (P = 0.02) (Fig. Roland Tacke and Michael Theisen, from Scientific Connections (Newtown, PA), who provided assistance with medical writing that was funded by AstraZeneca. is an employee and stockholder of AstraZeneca. Atorvastatin (10 or 20 mg) had a greater effect on blood sugar than the same doses of pravastatin or simvastatin in one study, while another showed that the higher-intensity statins such as atorvastatin, rosuvastatin and simvastatin increased the risk of newly diagnosed diabetes compared to treatment with fluvastatin or lovastatin over a 14-year period. However, the objective nature of the measurements and the small magnitude of changes observed with placebo in the first 6-week period suggest that changes by 12 weeks can be attributed to statin therapy. A recent analysis of the Framingham Offspring Study showed that LDL particle concentration was approximately twice as strongly related to CVD incidence as was LDL cholesterol (6). The population included 318 patients at baseline, of whom 136 were randomly assigned to RSV10, 119 to ATV10, and 63 to placebo. Lipoprotein particle concentrations were measured by nuclear magnetic resonance spectroscopy, LDL cholesterol was measured by β-quantification, and other lipoproteins were measured by standard methods at baseline, 6 weeks, and 12 weeks.